Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ambrx, Inc.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.